Mitochondria are the powerhouses of our cells, playing a critical role in metabolism, signaling, apoptosis (programmed cell death), and immune function. Once thought of as simple power generators, mitochondria are now recognized as dynamic regulators of cellular health and disease, and serve as critical signaling hubs. Mitochondrial dysfunction has been linked to a wide range of disorders—including neurodegeneration, metabolic disease, cancer, and rare genetic syndromes.

Mitochondria are not just the “powerhouse of the cell”.

BPGbio’s BPM31510 is engineered using lipid nano technology to be an NCE (novel chemical entity) delivery platform containing oxidized CoQ₁₀.

BPM31510 is a potential first-in-class mitochondrial metabolic regulator designed to restore cellular energy function across diseases driven by mitochondrial dysfunction. Delivered through a proprietary lipid nanodispersion platform that enables therapeutic exposure to oxidized CoQ10, BPM31510 targets a central biological pathway shared across rare genetic mitochondrial disorders, cancer, and tissue repair processes such as wound healing.

In cancer, mitochondrial metabolism is fundamentally rewired to support tumor growth and survival. BPM31510 targets this metabolic vulnerability by re-engaging mitochondrial oxidative function and selectively increasing reactive oxygen species stress in tumor cells, triggering cancer cell death while preserving metabolic stability in healthy tissues. This differentiated mechanism positions BPM31510 as a mitochondrial-targeted therapeutic platform spanning oncology and primary mitochondrial disease.